Two-stage matching-adjusted indirect comparison

被引:3
|
作者
Remiro-Azocar, Antonio [1 ,2 ]
机构
[1] Bayer PLC, Med Affairs Stat, 400 South Oak Way, Reading, Berks, England
[2] UCL, Dept Stat Sci, 1-19 Torrington Pl, London, England
关键词
Health technology assessment; Indirect treatment comparison; Matching-adjusted indirect comparison; Covariate adjustment; Covariate balance; Inverse probability of treatment weighting; Evidence synthesis; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ANCHORED INDIRECT COMPARISONS; GUANFACINE EXTENDED-RELEASE; PROPENSITY SCORE; INVERSE PROBABILITY; CAUSAL INFERENCE; VARIABLE SELECTION; PRACTICAL GUIDE; PERFORMANCE; TRIAL;
D O I
10.1186/s12874-022-01692-9
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Anchored covariate-adjusted indirect comparisons inform reimbursement decisions where there are no head-to-head trials between the treatments of interest, there is a common comparator arm shared by the studies, and there are patient-level data limitations. Matching-adjusted indirect comparison (MAIC), based on propensity score weighting, is the most widely used covariate-adjusted indirect comparison method in health technology assessment. MAIC has poor precision and is inefficient when the effective sample size after weighting is small. Methods A modular extension to MAIC, termed two-stage matching-adjusted indirect comparison (2SMAIC), is proposed. This uses two parametric models. One estimates the treatment assignment mechanism in the study with individual patient data (IPD), the other estimates the trial assignment mechanism. The first model produces inverse probability weights that are combined with the odds weights produced by the second model. The resulting weights seek to balance covariates between treatment arms and across studies. A simulation study provides proof-of-principle in an indirect comparison performed across two randomized trials. Nevertheless, 2SMAIC can be applied in situations where the IPD trial is observational, by including potential confounders in the treatment assignment model. The simulation study also explores the use of weight truncation in combination with MAIC for the first time. Results Despite enforcing randomization and knowing the true treatment assignment mechanism in the IPD trial, 2SMAIC yields improved precision and efficiency with respect to MAIC in all scenarios, while maintaining similarly low levels of bias. The two-stage approach is effective when sample sizes in the IPD trial are low, as it controls for chance imbalances in prognostic baseline covariates between study arms. It is not as effective when overlap between the trials' target populations is poor and the extremity of the weights is high. In these scenarios, truncation leads to substantial precision and efficiency gains but induces considerable bias. The combination of a two-stage approach with truncation produces the highest precision and efficiency improvements. Conclusions Two-stage approaches to MAIC can increase precision and efficiency with respect to the standard approach by adjusting for empirical imbalances in prognostic covariates in the IPD trial. Further modules could be incorporated for additional variance reduction or to account for missingness and non-compliance in the IPD trial.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] RELATIVE EFFICACY OF ADALIMUMAB VERSUS SECUKINUMAB IN ACTIVE ANKYLOSING SPONDYLITIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Betts, K. A.
    Mittal, M.
    Song, J.
    Skup, M.
    Joshi, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 98 - 99
  • [32] Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison
    Betts, Keith
    Mittal, Manish
    Joshi, Avani
    Song, Jinlin
    Bao, Yanjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB267 - AB267
  • [33] Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison
    Swallow, Elyse
    Pham, Timothy
    Patterson-Lomba, Oscar
    Yin, Lei
    Gomez-Lievano, Andres
    Liu, Jingyi
    Tencer, Tom
    Gupte-Singh, Komal
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
  • [34] Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
    Gupta, Vikas
    Mascarenhas, John
    Kremyanskaya, Marina
    Rampal, Raajit K.
    Talpaz, Moshe
    Kiladjian, Jean-Jacques
    Vannucchi, Alessandro M.
    Verstovsek, Srdan
    Colak, Gozde
    Dey, Debarshi
    Harrison, Claire
    BLOOD ADVANCES, 2023, 7 (18) : 5421 - 5432
  • [35] Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma
    Cai, Ling
    Roos, Jack
    Miranda, Paulo A. P.
    Liljas, Bengt
    Rule, Simon
    Wang, Michael
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1552 - 1557
  • [36] A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF BIMEKIZUMAB AND SECUKINUMAB AT 52 WEEKS FOR THE TREATMENT OF PSORIATIC ARTHRITIS
    Mease, P. J.
    Warren, R. B.
    Nash, P.
    Grouin, J. M.
    Willems, D.
    Taieb, V
    Eells, J.
    McInnes, I.
    VALUE IN HEALTH, 2023, 26 (12) : S16 - S16
  • [37] Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC
    Castro, Elena
    Wang, Di
    Walsh, Sarah
    Craigie, Samantha
    Haltner, Anja
    Nazari, Jonathan
    Niyazov, Alexander
    Samjoo, Imtiaz A.
    FUTURE ONCOLOGY, 2025,
  • [38] Matching-Adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-Term Effectiveness
    Paul, Friedemann
    Aktas, Orhan
    Pedersen, Mikkel
    Vilela, Francisco Sorio
    Patterson, Kristina
    Rampal, Nishi
    Cimbora, Daniel
    Cree, Bruce
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 144 - 145
  • [39] Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20
    Mt-Isa, Shahrul
    Abderhalden, Lauren A.
    Musey, Luwy
    Weiss, Thomas
    EXPERT REVIEW OF VACCINES, 2022, 21 (01) : 115 - 123
  • [40] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Vibeke Strand
    Keith A. Betts
    Manish Mittal
    Jinlin Song
    Martha Skup
    Avani Joshi
    Rheumatology and Therapy, 2017, 4 : 349 - 362